Clinical Trials | April 05, 2024
Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Application based on results from the TROPION-Breast01 Phase III trial
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Combination shows consistent benefit across prespecified post-progression outcomes
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Subscribe To Our Newsletter & Stay Updated
